CDC25 Inhibitors as Anticancer Agents Are Moving Forward

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

CDC25 Inhibitors as Anticancer Agents Are Moving Forward

Anti-Cancer Agents in Medicinal Chemistry, 8(8): 857-862.

Author(s): M.-C. Brezak, P. G. Kasprzyk, M.-O. Galcera, O. Lavergne and G P Prevost.

Affiliation: Discovery&Innovation, IPSEN, 5 Avenue du Canada, 91966, Les Ulis, France.


The identification of a CDC25 inhibitor to arrest the cell cycle closely followed the discovery of CDC25 by Russell and Nurse in 1986. Recent advances at the preclinical and clinical stages reinforce the rationale to consider CDC25 as a relevant target for a cancer treatment. Here, in order to exemplify recent drug discovery efforts, we present our own experience with various chemical series of CDC25 inhibitors. We discuss how we have progressed and how we are considering the next steps to define the clinical entry points and hopefully complete this target validation to generate a new class of therapeutic agents.


Cancer, phosphatase, CDC25, inhibitors, cell cycle, proliferation, agents, small molecules.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 8
First Page: 857
Last Page: 862
Page Count: 6
DOI: 10.2174/187152008786847701
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science